MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson’s role will be pivotal in ensuring the medical, ethical, and scientific integrity of Annovis’ clinical trials, particularly as the company prepares for its upcoming Phase 3 studies.
Dr. Peterson joins Annovis with extensive experience in academic research and the life sciences sector. He previously worked as a Senior Clinical Research Science Manager at Axogen, where his efforts were concentrated on therapies for nerve repair and regeneration. His career also includes positions at Ethicon and Exactech, and a significant tenure at the Department of Veterans Affairs. At the VA, Dr. Peterson spearheaded research on pressure ulcer prevention and fall risk assessment, focusing on enhancing the quality of life for veterans with spinal cord injuries.
Holding a Ph.D. in Biomedical Engineering from the University of Florida, Dr. Peterson has developed technologies to minimize clinical complications for at-risk patients. He has also been a principal investigator on studies funded by the Department of Defense and the VA, and has authored numerous peer-reviewed articles.
Cheng Fang, Ph.D., Senior Vice President of Research and Development at Annovis, expressed enthusiasm about Dr. Peterson’s arrival, noting his impressive track record and commitment to improving patient outcomes. Dr. Peterson echoed this sentiment, stating his eagerness to contribute to the clinical development of buntanetap and help advance therapies for neurodegenerative diseases.
Dr. Peterson’s appointment is seen as a crucial step for Annovis as it approaches the initiation of its pivotal Phase 3 studies, marking a significant moment in the company’s efforts to bring transformative treatments to patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.